Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients
Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of thi...
Saved in:
| Published in | Antimicrobial agents and chemotherapy Vol. 61; no. 12 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
01.12.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (
= 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], -0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter). |
|---|---|
| AbstractList | Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (
n
= 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter). Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation ( = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], -0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter). Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], -0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter). Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter). ABSTRACT Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation ( n = 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter). |
| Author | García, Benito Tejedor-Prado, Pilar Romano-Moreno, Silvia Barcia, Emilia Blasco-Navalpotro, Miguel Angel Medellín-Garibay, Susanna Edith Rubio-Álvaro, Noelia Rueda-Naharro, Aida |
| Author_xml | – sequence: 1 givenname: Susanna Edith surname: Medellín-Garibay fullname: Medellín-Garibay, Susanna Edith organization: Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain – sequence: 2 givenname: Silvia surname: Romano-Moreno fullname: Romano-Moreno, Silvia email: srm@uaslp.mx organization: Departamento de Farmacia y Tecnología de Medicamentos, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico srm@uaslp.mx – sequence: 3 givenname: Pilar surname: Tejedor-Prado fullname: Tejedor-Prado, Pilar organization: Hospital Universitario Severo Ochoa, Leganes, Spain – sequence: 4 givenname: Noelia surname: Rubio-Álvaro fullname: Rubio-Álvaro, Noelia organization: Hospital Universitario Severo Ochoa, Leganes, Spain – sequence: 5 givenname: Aida surname: Rueda-Naharro fullname: Rueda-Naharro, Aida organization: Hospital Universitario Severo Ochoa, Leganes, Spain – sequence: 6 givenname: Miguel Angel surname: Blasco-Navalpotro fullname: Blasco-Navalpotro, Miguel Angel organization: Hospital Universitario Severo Ochoa, Leganes, Spain – sequence: 7 givenname: Benito surname: García fullname: García, Benito organization: Hospital Universitario Severo Ochoa, Leganes, Spain – sequence: 8 givenname: Emilia surname: Barcia fullname: Barcia, Emilia organization: Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28893792$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kU1rFTEUhoNU7G1151qytODUfMxkMhvhMvhxoWIX2m3IZE68qZmkJjPC_Qf-bDPeWnQhBELIk-fl5D1DJyEGQOg5JZeUMvl6u-0vCWV1V9H2EdpQ0slKNJ04QRtChKhqSepTdJbzLSnnpiNP0CmTsuNtxzbo5y5Yv0AwgKPFH8HsdXBGe3wDYXZezy4GXNa8B3y912nSJn5zAWZn8vriRgcTp4NxAW_HyQWXZ0gw4uGA-1gMYYlLxiVkyaupYH1y85rgD3jnPb4uESUqP0WPrfYZnt3v5-jLu7ef-w_V1af3u357VemayrkS7SB5U1ugIxPADdNCMjM2DQykq5mmTBO9Al2rCa1HK4SVrbWUM27awfJz9ObovVuGCUZTspP26i65SaeDitqpf2-C26uv8YdqWkK4qIvg5b0gxe8L5FlNLhvwXgcosyracckIp1QW9NURNSnmnMA-xFCi1vJUKU_9Lk_RtuAXR1znianbuKRQfuJ_7Iu_x3gQ_2mW_wKMd6ap |
| CitedBy_id | crossref_primary_10_1080_17512433_2023_2295009 crossref_primary_10_1097_FTD_0000000000000801 crossref_primary_10_3389_fmicb_2021_649757 crossref_primary_10_1007_s40262_023_01213_x crossref_primary_10_1016_j_cmi_2020_07_005 crossref_primary_10_1007_s40262_020_00866_2 crossref_primary_10_1515_med_2018_0068 crossref_primary_10_1002_jcph_2375 crossref_primary_10_1093_jac_dkz158 crossref_primary_10_1136_ejhpharm_2020_002637 crossref_primary_10_3390_pharmaceutics15051411 crossref_primary_10_1007_s00228_023_03511_6 crossref_primary_10_1016_j_ijantimicag_2022_106579 crossref_primary_10_1128_AAC_01209_18 crossref_primary_10_1016_j_biopha_2022_113777 crossref_primary_10_1016_j_ijantimicag_2019_09_018 crossref_primary_10_1128_AAC_02543_18 crossref_primary_10_1016_j_cmi_2019_02_029 crossref_primary_10_3389_fphar_2022_1005791 crossref_primary_10_1111_jphp_13071 crossref_primary_10_3390_pharmaceutics12070638 |
| Cites_doi | 10.1007/BF01726369 10.1128/AAC.03147-14 10.1007/s40262-016-0475-3 10.1016/j.ijantimicag.2010.09.004 10.1093/cid/cir034 10.1016/j.jcrc.2012.02.003 10.1159/000180580 10.1038/psp.2013.24 10.1128/AAC.00330-16 10.1111/jcpt.12270 10.1016/S0169-2607(98)00067-4 10.1592/phco.29.11.1275 10.1086/491712 10.1128/AAC.01149-08 10.1128/AAC.01472-10 10.1007/BF01060893 10.1128/AAC.00168-11 10.1111/jcpt.12088 10.1093/jac/dkt402 10.1111/j.1365-2125.2010.03679.x 10.1111/j.1365-2710.2006.00762.x 10.7399/fh.2017.41.2.10591 10.1128/AAC.45.9.2460-2467.2001 10.1016/j.jcrc.2013.12.007 10.1097/CCM.0b013e3181961bff 10.1016/j.cmpb.2005.04.005 10.2165/00003088-200544100-00002 10.1097/FTD.0000000000000295 10.1128/AAC.37.2.281 10.1128/JCM.01388-06 10.1111/j.1365-2710.2004.00572.x 10.1038/psp.2013.14 10.2165/11318140-000000000-00000 10.1378/chest.11-1396 10.1186/2110-5820-1-26 10.1186/s13054-014-0654-2 10.1128/AAC.01708-10 10.1007/s40262-016-0435-y 10.1093/jac/dks328 10.1177/106002808902300408 10.1093/jac/dkv372 10.1128/AAC.01485-12 10.1128/AAC.01568-12 10.1002/9780470087978.ch8 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 American Society for Microbiology. Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
| Copyright_xml | – notice: Copyright © 2017 American Society for Microbiology. – notice: Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1128/AAC.01249-17 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Vancomycin Pharmacokinetics in Critically Ill Patients, Medellín-Garibay et al Vancomycin Pharmacokinetics in Critically Ill Patients |
| EISSN | 1098-6596 |
| ExternalDocumentID | 10_1128_AAC_01249_17 01249-17 28893792 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Consejo Nacional de Ciencia y Tecnología (CONACYT) grantid: 237235 funderid: https://doi.org/10.13039/501100003141 – fundername: Consejo Nacional de Ciencia y Tecnología (CONACYT) grantid: 237235 |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ - 0R 55 AAPBV ABFLS ADACO BXI HZ ZA5 AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-a418t-67b8354fe1d26e3c2a682cd55eb0942a12a0a354f97a014df66f87ff1323c7bf3 |
| IEDL.DBID | RPM |
| ISSN | 0066-4804 |
| IngestDate | Tue Sep 17 21:22:04 EDT 2024 Sat Oct 05 04:38:01 EDT 2024 Thu Sep 12 17:21:10 EDT 2024 Tue Dec 28 13:59:23 EST 2021 Wed Oct 16 01:00:09 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | vancomycin dosing recommendations intensive care mechanical ventilation stochastic simulations population pharmacokinetics |
| Language | English |
| License | Copyright © 2017 American Society for Microbiology. All Rights Reserved . https://doi.org/10.1128/ASMCopyrightv2 All Rights Reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a418t-67b8354fe1d26e3c2a682cd55eb0942a12a0a354f97a014df66f87ff1323c7bf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation Medellín-Garibay SE, Romano-Moreno S, Tejedor-Prado P, Rubio-Álvaro N, Rueda-Naharro A, Blasco-Navalpotro MA, García B, Barcia E. 2017. Influence of mechanical ventilation on the pharmacokinetics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 61:e01249-17. https://doi.org/10.1128/AAC.01249-17. |
| OpenAccessLink | https://aac.asm.org/content/aac/61/12/e01249-17.full.pdf |
| PMID | 28893792 |
| PQID | 1938203118 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5700364 proquest_miscellaneous_1938203118 crossref_primary_10_1128_AAC_01249_17 asm2_journals_10_1128_AAC_01249_17 pubmed_primary_28893792 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-12-01 |
| PublicationDateYYYYMMDD | 2017-12-01 |
| PublicationDate_xml | – month: 12 year: 2017 text: 2017-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2017 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | Lindbom, L, Pihlgren, P, Jonsson, EN (B40) 2005; 79 Contreiras, C, Legal, M, Lau, TT, Thalakada, R, Shalansky, S, Ensom, MH (B11) 2014; 67 Saugel, B, Gramm, C, Wagner, JY, Messer, M, Lahmer, T, Meidert, AS, Schmid, RM, Huber, W (B6) 2014; 29 Pea, F, Viale, P, Furlanut, M (B21) 2005; 44 Revilla, N, Martin-Suarez, A, Perez, MP, Gonzalez, FM, del Mar Fernandez de Gatta, M (B24) 2010; 70 Baptista, JP, Roberts, JA, Sousa, E, Freitas, R, Deveza, N, Pimentel, J (B13) 2014; 18 Rybak, MJ, Lomaestro, BM, Rotschafer, JC, Moellering, RC, Craig, WA, Billeter, M, Dalovisio, JR, Levine, DP (B3) 2009; 29 Vuagnat, A, Stern, R, Lotthe, A, Schuhmacher, H, Duong, M, Hoffmeyer, P, Bernard, L (B16) 2004; 29 Jonsson, EN, Karlsson, MO (B41) 1999; 58 van Hal, SJ, Paterson, DL, Lodise, TP (B8) 2013; 57 Cockcroft, DW, Gault, MH (B39) 1976; 16 Llopis-Salvia, P, Jiménez-Torres, NV (B25) 2006; 31 Wang, G, Hindler, JF, Ward, KW, Bruckner, DA (B36) 2006; 44 Zelenitsky, S, Alkurdi, N, Weber, Z, Ariano, R, Zhanel, G (B35) 2011; 55 Jeurissen, A, Sluyts, I, Rutsaert, R (B29) 2011; 37 Rybak, MJ (B4) 2006; 42 van Maarseveen, EM, Gipmans, S, Vasbinder, E, Petjak, M, van Zanten, AR (B23) 2016; 38 Perkins, MW, Dasta, JF, DeHaven, B (B31) 1989; 23 Liu, C, Bayer, A, Cosgrove, SE, Daum, RS, Fridkin, SK, Gorwitz, RJ, Kaplan, SL, Karchmer, AW, Levine, DP, Murray, BE, Rybak, MJ, Talan, DA, Chambers, HF (B1) 2011; 52 Carballo, N, De Antonio-Cusco, M, Echeverria-Esnal, D, Luque, S, Salas, E, Grau, S (B2) 2017; 41 Minkute, R, Briedis, V, Steponaviciute, R, Vitkauskiene, A, Maciulaitis, R (B34) 2013; 38 Waineo, MF, Kuhn, TC, Brown, DL (B17) 2015; 40 Verrall, AJ, Llorin, R, Tam, VH, Lye, DC, Sulaiman, Z, Zhong, L, Archuleta, S, Fisher, DA (B15) 2012; 67 Roberts, JA, Taccone, FS, Udy, AA, Vincent, JL, Jacobs, F, Lipman, J (B19) 2011; 55 Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, Hempel, G (B26) 2017 Lamer, C, de Beco, V, Soler, P, Calvat, S, Fagon, JY, Dombret, MC, Farinotti, R, Chastre, J, Gibert, C (B32) 1993; 37 Williams, PJ, Kim, YH, Ette, EI, Ette, EI, Williams, PJ (B45) 2007 Smith, BS, Yogaratnam, D, Levasseur-Franklin, KE, Forni, A, Fong, J (B28) 2012; 141 Prybylski, JP (B7) 2017; 56 Sheiner, LB, Beal, SL (B44) 1981; 9 Wysocki, M, Delatour, F, Faurisson, F, Rauss, A, Pean, Y, Misset, B, Thomas, F, Timsit, JF, Similowski, T, Mentec, H, Mier, L, Dreyfuss, D (B12) 2001; 45 Mould, DR, Upton, RN (B43) 2013; 2 Cristallini, S, Hites, M, Kabtouri, H, Roberts, JA, Beumier, M, Cotton, F, Lipman, J, Jacobs, F, Vincent, JL, Creteur, J, Taccone, FS (B14) 2016; 60 Alvarez, R, Lopez Cortes, LE, Molina, J, Cisneros, JM, Pachon, J (B9) 2016; 60 Keizer, RJ, Karlsson, MO, Hooker, A (B42) 2013; 2 Norton, K, Ingram, PR, Heath, CH, Manning, L (B38) 2014; 69 Holmes, NE, Turnidge, JD, Munckhof, WJ, Robinson, JO, Korman, TM, O'Sullivan, MV, Anderson, TL, Roberts, SA, Warren, SJ, Gao, W, Howden, BP, Johnson, PD (B5) 2013; 57 Roberts, JA, Lipman, J (B18) 2009; 37 Spapen, HD, Janssen van Doorn, K, Diltoer, M, Verbrugghe, W, Jacobs, R, Dobbeleir, N, Honore, PM, Jorens, PG (B37) 2011; 1 Georges, H, Leroy, O, Alfandari, S, Guery, B, Roussel-Delvallez, M, Dhennain, C, Beaucaire, G (B33) 1997; 16 Udy, AA, Roberts, JA, Boots, RJ, Paterson, DL, Lipman, J (B20) 2010; 49 Saugel, B, Nowack, MC, Hapfelmeier, A, Umgelter, A, Schultheiss, C, Thies, P, Phillip, V, Eyer, F, Schmid, RM, Huber, W (B30) 2013; 28 Bosso, JA, Nappi, J, Rudisill, C, Wellein, M, Bookstaver, PB, Swindler, J, Mauldin, PD (B10) 2011; 55 Pea, F, Furlanut, M, Negri, C, Pavan, F, Crapis, M, Cristini, F, Viale, P (B22) 2009; 53 Medellín-Garibay, SE, Ortiz-Martin, B, Rueda-Naharro, A, Garcia, B, Romano-Moreno, S, Barcia, E (B27) 2016; 71 e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_41_2 e_1_3_2_40_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_21_2 e_1_3_2_42_2 Contreiras C (e_1_3_2_12_2) 2014; 67 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 |
| References_xml | – volume: 16 start-page: 385 year: 1997 end-page: 388 ident: B33 article-title: Pulmonary disposition of vancomycin in critically ill patients publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/BF01726369 contributor: fullname: Beaucaire, G – volume: 60 start-page: 2601 year: 2016 end-page: 2609 ident: B9 article-title: Optimizing the clinical use of vancomycin publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.03147-14 contributor: fullname: Pachon, J – year: 2017 ident: B26 article-title: Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0475-3 contributor: fullname: Hempel, G – volume: 37 start-page: 75 year: 2011 end-page: 77 ident: B29 article-title: A higher dose of vancomycin in continuous infusion is needed in critically ill patients publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2010.09.004 contributor: fullname: Rutsaert, R – volume: 52 start-page: 285 year: 2011 end-page: 292 ident: B1 article-title: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary publication-title: Clin Infect Dis doi: 10.1093/cid/cir034 contributor: fullname: Chambers, HF – volume: 28 start-page: 9 year: 2013 end-page: 13 ident: B30 article-title: Continuous intravenous administration of vancomycin in medical intensive care unit patients publication-title: J Crit Care doi: 10.1016/j.jcrc.2012.02.003 contributor: fullname: Huber, W – volume: 16 start-page: 31 year: 1976 end-page: 41 ident: B39 article-title: Prediction of creatinine clearance from serum creatinine publication-title: Nephron doi: 10.1159/000180580 contributor: fullname: Gault, MH – volume: 2 start-page: e50 year: 2013 ident: B42 article-title: Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1038/psp.2013.24 contributor: fullname: Hooker, A – volume: 60 start-page: 4750 year: 2016 end-page: 4756 ident: B14 article-title: New regimen for continuous infusion of vancomycin in critically ill patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00330-16 contributor: fullname: Taccone, FS – volume: 40 start-page: 259 year: 2015 end-page: 265 ident: B17 article-title: The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.12270 contributor: fullname: Brown, DL – volume: 58 start-page: 51 year: 1999 end-page: 64 ident: B41 article-title: Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM publication-title: Comput Methods Programs Biomed doi: 10.1016/S0169-2607(98)00067-4 contributor: fullname: Karlsson, MO – volume: 29 start-page: 1275 year: 2009 end-page: 1279 ident: B3 article-title: Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists publication-title: Pharmacotherapy doi: 10.1592/phco.29.11.1275 contributor: fullname: Levine, DP – volume: 42 start-page: S35 year: 2006 end-page: S39 ident: B4 article-title: The pharmacokinetic and pharmacodynamic properties of vancomycin publication-title: Clin Infect Dis doi: 10.1086/491712 contributor: fullname: Rybak, MJ – volume: 53 start-page: 1863 year: 2009 end-page: 1867 ident: B22 article-title: Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01149-08 contributor: fullname: Viale, P – volume: 55 start-page: 3627 year: 2011 end-page: 3630 ident: B35 article-title: Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01472-10 contributor: fullname: Zhanel, G – volume: 9 start-page: 503 year: 1981 end-page: 512 ident: B44 article-title: Some suggestions for measuring predictive performance publication-title: J Pharmacokinet Biopharm doi: 10.1007/BF01060893 contributor: fullname: Beal, SL – volume: 67 start-page: 126 year: 2014 end-page: 132 ident: B11 article-title: Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy publication-title: Can J Hosp Pharm contributor: fullname: Ensom, MH – start-page: 223 year: 2007 end-page: 245 ident: B45 article-title: The epistemology of pharmacometrics publication-title: Pharmacometrics: the science of quantitative pharmacology ;John Wiley & Sons ;Hoboken, NJ contributor: fullname: Williams, PJ – volume: 55 start-page: 5475 year: 2011 end-page: 5479 ident: B10 article-title: Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00168-11 contributor: fullname: Mauldin, PD – volume: 38 start-page: 462 year: 2013 end-page: 467 ident: B34 article-title: Augmented renal clearance—an evolving risk factor to consider during the treatment with vancomycin publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.12088 contributor: fullname: Maciulaitis, R – volume: 69 start-page: 805 year: 2014 end-page: 808 ident: B38 article-title: Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkt402 contributor: fullname: Manning, L – volume: 70 start-page: 201 year: 2010 end-page: 212 ident: B24 article-title: Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2010.03679.x contributor: fullname: del Mar Fernandez de Gatta, M – volume: 31 start-page: 447 year: 2006 end-page: 454 ident: B25 article-title: Population pharmacokinetic parameters of vancomycin in critically ill patients publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2006.00762.x contributor: fullname: Jiménez-Torres, NV – volume: 41 start-page: 187 year: 2017 end-page: 203 ident: B2 article-title: Community-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in critically-ill patients: systematic review publication-title: Farm Hosp doi: 10.7399/fh.2017.41.2.10591 contributor: fullname: Grau, S – volume: 45 start-page: 2460 year: 2001 end-page: 2467 ident: B12 article-title: Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.45.9.2460-2467.2001 contributor: fullname: Dreyfuss, D – volume: 29 start-page: 351 year: 2014 end-page: 355 ident: B6 article-title: Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients publication-title: J Crit Care doi: 10.1016/j.jcrc.2013.12.007 contributor: fullname: Huber, W – volume: 37 start-page: 840 year: 2009 end-page: 851 ident: B18 article-title: Pharmacokinetic issues for antibiotics in the critically ill patient publication-title: Crit Care Med doi: 10.1097/CCM.0b013e3181961bff contributor: fullname: Lipman, J – volume: 79 start-page: 241 year: 2005 end-page: 257 ident: B40 article-title: PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM publication-title: Comput Methods Programs Biomed doi: 10.1016/j.cmpb.2005.04.005 contributor: fullname: Jonsson, EN – volume: 44 start-page: 1009 year: 2005 end-page: 1034 ident: B21 article-title: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200544100-00002 contributor: fullname: Furlanut, M – volume: 38 start-page: 398 year: 2016 end-page: 401 ident: B23 article-title: Switching from intermittent to continuous infusion of vancomycin in critically ill patients: toward a more robust exposure publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000295 contributor: fullname: van Zanten, AR – volume: 37 start-page: 281 year: 1993 end-page: 286 ident: B32 article-title: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.37.2.281 contributor: fullname: Gibert, C – volume: 44 start-page: 3883 year: 2006 end-page: 3886 ident: B36 article-title: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period publication-title: J Clin Microbiol doi: 10.1128/JCM.01388-06 contributor: fullname: Bruckner, DA – volume: 29 start-page: 351 year: 2004 end-page: 357 ident: B16 article-title: High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2004.00572.x contributor: fullname: Bernard, L – volume: 2 start-page: e38 year: 2013 ident: B43 article-title: Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1038/psp.2013.14 contributor: fullname: Upton, RN – volume: 49 start-page: 1 year: 2010 end-page: 16 ident: B20 article-title: Augmented renal clearance: implications for antibacterial dosing in the critically ill publication-title: Clin Pharmacokinet doi: 10.2165/11318140-000000000-00000 contributor: fullname: Lipman, J – volume: 141 start-page: 1327 year: 2012 end-page: 1336 ident: B28 article-title: Introduction to drug pharmacokinetics in the critically ill patient publication-title: Chest doi: 10.1378/chest.11-1396 contributor: fullname: Fong, J – volume: 1 start-page: 26 year: 2011 ident: B37 article-title: Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients publication-title: Ann Intensive Care doi: 10.1186/2110-5820-1-26 contributor: fullname: Jorens, PG – volume: 18 start-page: 654 year: 2014 ident: B13 article-title: Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram publication-title: Crit Care doi: 10.1186/s13054-014-0654-2 contributor: fullname: Pimentel, J – volume: 55 start-page: 2704 year: 2011 end-page: 2709 ident: B19 article-title: Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01708-10 contributor: fullname: Lipman, J – volume: 56 start-page: 263 year: 2017 end-page: 272 ident: B7 article-title: A strategy for dosing vancomycin to therapeutic targets using only trough concentrations publication-title: Clin Pharmacokinet doi: 10.1007/s40262-016-0435-y contributor: fullname: Prybylski, JP – volume: 67 start-page: 2970 year: 2012 end-page: 2973 ident: B15 article-title: Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections publication-title: J Antimicrob Chemother doi: 10.1093/jac/dks328 contributor: fullname: Fisher, DA – volume: 23 start-page: 316 year: 1989 end-page: 323 ident: B31 article-title: Physiologic implications of mechanical ventilation on pharmacokinetics publication-title: DICP doi: 10.1177/106002808902300408 contributor: fullname: DeHaven, B – volume: 71 start-page: 471 year: 2016 end-page: 479 ident: B27 article-title: Pharmacokinetics of vancomycin and dosing recommendations for trauma patients publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkv372 contributor: fullname: Barcia, E – volume: 57 start-page: 1654 year: 2013 end-page: 1663 ident: B5 article-title: Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01485-12 contributor: fullname: Johnson, PD – volume: 57 start-page: 734 year: 2013 end-page: 744 ident: B8 article-title: Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01568-12 contributor: fullname: Lodise, TP – ident: e_1_3_2_41_2 doi: 10.1016/j.cmpb.2005.04.005 – ident: e_1_3_2_2_2 doi: 10.1093/cid/cir034 – ident: e_1_3_2_38_2 doi: 10.1186/2110-5820-1-26 – ident: e_1_3_2_4_2 doi: 10.1592/phco.29.11.1275 – ident: e_1_3_2_43_2 doi: 10.1038/psp.2013.24 – ident: e_1_3_2_44_2 doi: 10.1038/psp.2013.14 – ident: e_1_3_2_6_2 doi: 10.1128/AAC.01485-12 – ident: e_1_3_2_31_2 doi: 10.1016/j.jcrc.2012.02.003 – ident: e_1_3_2_10_2 doi: 10.1128/AAC.03147-14 – ident: e_1_3_2_26_2 doi: 10.1111/j.1365-2710.2006.00762.x – ident: e_1_3_2_25_2 doi: 10.1111/j.1365-2125.2010.03679.x – ident: e_1_3_2_39_2 doi: 10.1093/jac/dkt402 – ident: e_1_3_2_29_2 doi: 10.1378/chest.11-1396 – ident: e_1_3_2_11_2 doi: 10.1128/AAC.00168-11 – ident: e_1_3_2_20_2 doi: 10.1128/AAC.01708-10 – ident: e_1_3_2_30_2 doi: 10.1016/j.ijantimicag.2010.09.004 – ident: e_1_3_2_9_2 doi: 10.1128/AAC.01568-12 – ident: e_1_3_2_45_2 doi: 10.1007/BF01060893 – ident: e_1_3_2_5_2 doi: 10.1086/491712 – ident: e_1_3_2_40_2 doi: 10.1159/000180580 – volume: 67 start-page: 126 year: 2014 ident: e_1_3_2_12_2 article-title: Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy publication-title: Can J Hosp Pharm contributor: fullname: Contreiras C – ident: e_1_3_2_24_2 doi: 10.1097/FTD.0000000000000295 – ident: e_1_3_2_3_2 doi: 10.7399/fh.2017.41.2.10591 – ident: e_1_3_2_14_2 doi: 10.1186/s13054-014-0654-2 – ident: e_1_3_2_28_2 doi: 10.1093/jac/dkv372 – ident: e_1_3_2_46_2 doi: 10.1002/9780470087978.ch8 – ident: e_1_3_2_42_2 doi: 10.1016/S0169-2607(98)00067-4 – ident: e_1_3_2_22_2 doi: 10.2165/00003088-200544100-00002 – ident: e_1_3_2_23_2 doi: 10.1128/AAC.01149-08 – ident: e_1_3_2_8_2 doi: 10.1007/s40262-016-0435-y – ident: e_1_3_2_21_2 doi: 10.2165/11318140-000000000-00000 – ident: e_1_3_2_15_2 doi: 10.1128/AAC.00330-16 – ident: e_1_3_2_33_2 doi: 10.1128/AAC.37.2.281 – ident: e_1_3_2_34_2 doi: 10.1007/BF01726369 – ident: e_1_3_2_7_2 doi: 10.1016/j.jcrc.2013.12.007 – ident: e_1_3_2_37_2 doi: 10.1128/JCM.01388-06 – ident: e_1_3_2_27_2 doi: 10.1007/s40262-016-0475-3 – ident: e_1_3_2_13_2 doi: 10.1128/AAC.45.9.2460-2467.2001 – ident: e_1_3_2_35_2 doi: 10.1111/jcpt.12088 – ident: e_1_3_2_16_2 doi: 10.1093/jac/dks328 – ident: e_1_3_2_18_2 doi: 10.1111/jcpt.12270 – ident: e_1_3_2_32_2 doi: 10.1177/106002808902300408 – ident: e_1_3_2_17_2 doi: 10.1111/j.1365-2710.2004.00572.x – ident: e_1_3_2_36_2 doi: 10.1128/AAC.01472-10 – ident: e_1_3_2_19_2 doi: 10.1097/CCM.0b013e3181961bff |
| SSID | ssj0006590 |
| Score | 2.4202054 |
| Snippet | Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin... ABSTRACT Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin... |
| SourceID | pubmedcentral proquest crossref asm2 pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| SubjectTerms | Anti-Bacterial Agents Clinical Therapeutics Creatinine Critical Illness Respiration, Artificial Vancomycin |
| Title | Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28893792 https://journals.asm.org/doi/10.1128/AAC.01249-17 https://search.proquest.com/docview/1938203118 https://pubmed.ncbi.nlm.nih.gov/PMC5700364 |
| Volume | 61 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swED4kBlJ0KVr3EfcRMEWbKbItiqKo0TAaxClceEiCbAIlkYgRWw4qe9A_6M_unSQ6cYMuAbSJFAXdUffgd98BfJNcx5znlNcQgSfyyHra16FnFI9TEYthzqneefpLnl-Ji5vwZg9CVwtTg_azdN4vFst-Mb-tsZX3y2zgcGKD2XRMnOyBFIN92EcFdSF6-_uVYZNYQVvqCTUUDu3O1WA0GveH1G3Z86n5HldkrOkQtKPLJd-1TE_czX9Rk4_M0NlreNX6j2zUvOcb2DNFFw6ajpJVF15M27PyLpzMGlbq6pRdPhRZlafshM0e-Kqrt_Bn4hqVsJVlU0O1wCQ6dk1IogYrx_BCV3E78w6XoKfRjGtUnNWywlWZo-KlBqAsrRhxX82LzWpTMlxkQ5k5hsNcf4VFxSaLBZs13K7lO7g6-3E5PvfaBg2eFr5aezJKKW9kjZ9zaYKMa6l4loehSTFq5NrneqhpQBxpDMVyK6VVkbUYAQdZlNrgPXSKVWEOgdlcCkNcbFYHIkZ1kblSVvE05NYXmvfgK8koaXdYmdTBC1cJyjSpZZr4UQ--Owkm9w1Zx3_GHTvxJrib6IhEFwa_RYLuLLpEAUZdPfjQiHv7JKcuPYh2FGE7gJi6d--gAteM3a3Cfnz2zE_wkpM_UeNoPkNn_XtjvqA3tE6PMA6Y_Dyq98BfgMgKKQ |
| link.rule.ids | 230,315,730,783,787,888,27938,27939,53808,53810 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB4tRTwuPAos5WkQ7GnTJo7jOMeqYtXCdtVDt9pb5Dwsqm3T1bY9hF_Az2Ymibt0EQeQcvNLTj7HM-PP3wB8klxHnGcU1xC-I7LQONrTgZMrHiUiEm7G6b7z-EwOz8XXi-DiAAJ7F6Yi7afJvFsslt1i_r3iVl4t057lifUm4wFpsvtS9O7AXVyvrrJOevMDlkEdWsHd1BHKFZbvzlWv3x90Xcq37HiUfo8r2q7pGLSl10u-vzf9YXDe5k3-thGdPIaZnULNP7nsbjdJN_1xS93xn-f4BB41pinr18VP4SAv2nCvTlZZtuH-uDmGb8PRpBa8Lo_Z9Ob-1vqYHbHJjRR2-Qx-jmwOFLYybJzTNWNCBZsRSamm4TF80ArdtbzEIag3ajFDTK6WJY7KrMov5RZlSclIVmtebFfbNcNBthT0Y1jNpm5YlGy0WLBJLRu7fg7nJ1-mg6HT5H5wtPDUxpFhQiEpk3sZl7mfci0VT7MgyBN0SLn2uHY1VYhCjV5eZqQ0KjQGnWs_DRPjv4BWsSryl8BMJkVOMm9G-yJCJMpMKaN4EnDjCc078JE-ftws3nVc-UVcxQiWuAJL7IUd-GyhEV_VOiB_qffB4ibGhUqnL7rI8V3EaCmjteWjQ9eBwxpHu54sDjsQ7iFsV4FEwPdLEDeVGHiDk1f_3fI9PBhOx6fx6ejs22t4yMlsqeg6b6C1ud7mb9Ho2iTvqiX2C_GOKyM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD6CIqa9cCmMlatBsKclaRzHcR6rQrUCnfKwTRMvkZPYolqbVqR5CL-An41PLt06xMukvOXYlqPPOefYn78D8JFTGVKa4b4G8yyWBdqSrvQtJWiYsJANM4r3nWen_OScfb30L2-U-qpJ-2kyt_PF0s7nP2tu5XqZOh1PzIlmY9Rk9zhz1pl27sMDH1WqukS9_Qlzv9leMR7VYmLIOs47Fc5oNLaHWHPZcrEEHxXosvEotCeLJd31T_8Enbe5kzec0eQx_Oim0XBQruxyk9jp71sKj3ea5xN41IaoZNSYPIV7Ku_Dw6ZoZdWHvVl7HN-Ho6gRvq6Oydn1Pa7imByR6FoSu3oGf6ZdLRSy0mSm8LoxooNcIFmpoeMR85hodNvyygyBvWGLC4PN1bIyo5JO7RdrjJKkIiivNc_LVVkQM0iJm3_EmHUlHBYVmS4WJGrkY4vncD75cjY-sdoaEJZkrthYPEhwa0orN6NceSmVXNA0832VmMSUSpfKoUSDMJAm28s051oEWpsk20uDRHsH0MtXuToEojPOFMq9aemx0CCSZ0JoQROfapdJOoAPCIC4XcRFXOdHVMQGMHENmNgNBvCpg0e8bvRA_mP3vsNObBYsnsLIXJlvEZuI2URdnknsBvCiwdK2pw6LAwh2ULY1QDHw3TcGO7UoeIuVl3du-Q72os-T-Pv09Nsr2KcYvdSsndfQ2_wq1RsTe22St_Uq-wsl4i2a |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+Mechanical+Ventilation+on+the+Pharmacokinetics+of+Vancomycin+Administered+by+Continuous+Infusion+in+Critically+Ill+Patients&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Medell%C3%ADn-Garibay%2C+Susanna+Edith&rft.au=Romano-Moreno%2C+Silvia&rft.au=Tejedor-Prado%2C+Pilar&rft.au=Rubio-%C3%81lvaro%2C+Noelia&rft.date=2017-12-01&rft.eissn=1098-6596&rft.volume=61&rft.issue=12&rft_id=info:doi/10.1128%2FAAC.01249-17&rft_id=info%3Apmid%2F28893792&rft.externalDocID=28893792 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |